aBLA Filing Intelligence & Biosimilar Opportunity

Briumvi

Ublituximab-Xiiy

Immunomodulators

Intravenous Injectable

Approval Date

28-Dec-22

Data Exclusivity Expiry

28-Dec-26

Market Exclusivity Expiry

28-Dec-34

Commercial snapshot

Market performance & projections

Revenue ($M)

607

CAGR (%)

0.3248

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

785

2027

1069

2028

1574

2029

1870

2030

2168

2031

2473

2032

2786

Molecule profile

Details & specifications

Molecule

Ublituximab-Xiiy

Innovator

TG THERAPEUTICS, INC.

Dosage Form

Intravenous Injectable

Strength

25 mg/mL

Therapeutic Category

Immunomodulators

Usage

To treat relapsing forms of multiple sclerosis

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.